

PRESS RELEASE

18 MARCH 2016

Oncimmune Signs Agreement with Accu Reference

U.S.-based clinical laboratory to offer Oncimmune's *EarlyCDT[®]-Lung*, a blood test to aid in the risk assessment and early detection of lung cancer

Nottingham, UK and De Soto, KS, US – 18 March 2016: Oncimmune, a leader in early cancer detection, today announced a multi-year partnership with Accu Reference Medical Lab (Accu Reference), a state-of-the-art medical testing laboratory service that provides a complete range of tests for diagnosis, screening or evaluation of diseases and health conditions.

Accu Reference will offer Oncimmune's *EarlyCDT[®]-Lung* test to its rapidly growing physician account base in over 15 states including primary care physicians and pulmonologists for use with low dose computed tomography (CT) lung cancer screening programs. No financial details are disclosed.

EarlyCDT-Lung is a simple blood test to aid in the risk assessment and early detection of lung cancer. The test measures a panel of seven autoantibodies to detect the presence of lung cancer and has been developed so that individuals at high risk of developing lung cancer can benefit from an increased chance that lung cancer can be detected at the earliest possible stages, when treatment can be most successful.

Greg Stanley, President of Commercial Operations, Oncimmune said: *"This agreement will allow more physicians to access the EarlyCDT-Lung test and provide patients at risk of developing lung cancer with information that could positively impact their health."*

"Accu Reference Medical Lab continues to be a leader in bringing innovative diagnostic tools to our clients and we look forward to offering EarlyCDT-Lung," said Konstantin Bas, CEO of Accu Reference. "EarlyCDT-Lung offers a complementary approach to annual CT screening and we believe it has the potential to make a real difference in the risk assessment and early detection of lung cancer."

EarlyCDT-Lung is being used in the world's largest randomised trial for the early detection of lung cancer using biomarkers ever conducted; the National Health Service (NHS) Scotland ECLS study of more than 10,000 high-risk smokers. Early results were [recently presented at the 16th World Conference on Lung Cancer](#); showing a high cancer detection rate with the majority of these cancers being early stage, resulting in better than expected test performance.

About Oncimmune



Oncimmune is an industry leader in early cancer detection. The company has pioneered the development of autoantibody assay technologies that have the potential to allow earlier cancer detection than other methods and can be applied to a very wide range of solid tumour types. The Company's proprietary *EarlyCDT* technology platform was launched in 2009 and *EarlyCDT-Lung* is available through physicians in the US and also privately in the UK and other regions. *EarlyCDT* tests for liver and ovarian cancer are in final validation.

Oncimmune is headquartered in Nottingham, United Kingdom with testing facilities in the US.

For more information: www.oncimmune.com

About Accu Reference Medical Laboratory (<http://www.accureference.com>)

Accu Reference is a state-of-the-art medical testing laboratory service that provides a complete range of tests for diagnosis, screening or evaluation of diseases and health conditions. We are certified under the federal government's Clinical Laboratory Improvement Amendments (CLIA) and operate in compliance with all governmental regulations. We use the latest diagnostic technology.

Media Contacts:

Chris Gardner, Matthew Neal, Lindsey Neville

Consilium Strategic Communications

oncimmune@consilium-comms.com

+44 (0) 20 3709 5813